Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Rhinomed.
RELATED STOCKHEAD STORIES
Health & Biotech
Health: Neuren’s secondary drug shows more efficacy in mice, shares rise 50pc
Health & Biotech
Rhinomed breathing easy thanks to strong March quarter, shares rise 26pc
News
Quarterlies: Marley Spoon is spending now to profit later, aims to break even by 2020
Health & Biotech
Kim Kardashian is having a CBD baby shower. Has cannabis peaked?
Health & Biotech
Two medical device smallcaps are up, one is down after a soft quarterly
Health & Biotech
Weed week: wtf happened with MMJ?
Health & Biotech
Weed week: here’s all the news driving ASX cannabis stocks
Health & Biotech
Weed week: it’s reefer madness as global pot stocks pass $6b in fund raising
Health & Biotech
These seven ASX-listed pot stocks are hoping for a US high
Health & Biotech
Rhinomed does US deal to put cannabis up your nose
Health & Biotech
Expert view: why it’s a critical time for investment in ASX small cap health stocks
Health & Biotech
Rhinomed soars as it closes a deal to ‘nasally deliver’ cannabis to Americans
Health & Biotech
The US is already a monster cannabis market – and it’s not even legal there yet
Health & Biotech
Canada’s got a nice marijuana buzz but US is the real prize for ASX pot stocks
Health & Biotech
Top tips for investing in ASX-listed biotechs
Health & Biotech
A whiff of profit from Rhinomed’s nose clips
Health & Biotech
